Effect of dexmedetomidine on intrapulmonary shunt in patients with sevoflurane maintained during one-lung ventilation
A case–control study
Yewen Wang, MSa, Chunzhi Gong, MDa, Fei Yu, MDa, Quanyi Zhang, MDa,*

Abstract
Background: The effects of dexmedetomidine on the circulatory system are complex. It is difficult to predict its effects on intrapulmonary shunts and hypoxic pulmonary vasoconstriction in patients with one-lung ventilation. This study aimed to investigate the effect of dexmedetomidine on intrapulmonary shunt in patients with sevoflurane during one-lung ventilation.

Methods: Forty patients requiring thoracoscopic lobectomy were randomly divided into the dexmedetomidine group (Group D, n = 20) and the normal saline group (Group N, n = 20). The arterial partial pressure of oxygen (PaO₂), pulmonary shunt fraction (Qs/Qt), mean end-tidal sevoflurane concentration, mean arterial pressure, and heart rate were compared between the 2 groups at 3 time points: (i) after 5 minutes of two-lung ventilation (T0), (ii) after 30 minutes of one-lung ventilation (OLV) (T1), and (iii) after 45 minutes of OLV (T2). The dosage of sevoflurane from the beginning of OLV to T2 was calculated.

Results: There were no significant differences in age, body mass index, and FEV1/FVC between Groups D and N (P > .05). At T0, T1, and T2, the PaO₂ levels of Group D and Group N were similar (P > .05), and the PaO₂ levels of Group D and Group N decreased after OLV. The Qs/Qt level of Groups D and N were similar at T0 (P > .05), and the level of Groups D and N at T1 and T2 was higher than that at T0. The Qs/Qt of Group D was statistically significantly lower than that of Group N at T1 and T2 (P < .05).

Conclusion: Compared with the control group, we found that dexmedetomidine can reduce the intrapulmonary shunt fraction and improve the body’s status during OLV.

Abbreviations: BIS = bispectral index monitoring, HPV = hypoxic pulmonary vasoconstriction, HR = heart rate, MAP = mean arterial pressure, OLV = one-lung ventilation, PaO₂ = partial pressure of oxygen.

Keywords: dexmedetomidine, intrapulmonary shunt, one-lung ventilation, video-assisted thoracic surgeries
Ethics Committee has approved of the Affiliated Hospital of Binzhou Medical College (KT-023). After written informed consent 1 day before surgery, 40 patients requiring 1-lung ventilation (OLV) for thoracic surgery in Binzhou Medical University Hospital between September 2021 to January 2022 were randomly assigned to receive dexmedetomidine (Group D) or normal saline (Group N) during anesthesia.

2.2. Sample size determined
The sample size was estimated concerning similar published studies.\[^{[13]}\] \( \frac{Q_S}{Q_T} \) was the primary outcome index of the study, so \( \frac{Q_S}{Q_T} \) at the OLV-30 minutes time point in the reference was selected as the index for sample size calculation. The mean value of \( \frac{Q_S}{Q_T} \) in the dexmedetomidine group was 24.5 ± 3.5, and the mean value of \( \frac{Q_S}{Q_T} \) in the saline group was 30.7 ± 2.8, with an overall standard deviation of approximately 4.5. We performed efficacy analysis using Origin software. When the power is > 0.8, the sample size needs to be > 10 cases.

2.3. Inclusion and exclusion criteria

2.3.1. Inclusion criteria. 18–65 years, ASA I-III, patients who would receive 1-lung ventilation for Video-assisted thoracic surgeries.

2.3.2. Exclusion criteria. Renal insufficiency, liver dysfunction or ischemic or valvular heart disease, long-term alcohol, opioid, or sedative-hypnotic drug addiction and dependency history, and neuropsychiatric diseases, intubation failure, bispectral index monitoring (BIS) < 40 or BIS > 60 in surgery and \( \text{SpO}_2 < 90\% \) during the operation.

2.4. Methods
All patients had fasted before surgeries; in the operating theater, ECG, \( \text{SpO}_2 \), NIBP, and other monitoring were placed. Oxygen inhalation was performed by mask, and a radial artery catheter was placed under local anesthesia. Before the induction, a loading dose of dexmedetomidine was infused continuously at a rate of 0.75\( \mu \text{g} \times \text{kg}^{-1} \) within 10 to 15 minutes in Group D. The same amount of normal saline was infused in Group N. Anesthesia induction was performed with midozolam 0.05 mg/kg, etomidate 0.3 mg/kg, sufentanil 0.5 \( \mu \text{g} \times \text{kg}^{-1} \) and vecuronium 0.1 mg/kg. After breath was controlled for about 5 minutes, intubation was performed under a visual laryngoscope with a double-lumen tube. The choice of a double-lumen tube depends on the surgical site. The left double-lumen tube was selected for the right thoracotomy, and the right double-lumen tube were chosen for the left thoracotomy. The default size of the catheter is 37F for males and 35F for females. After intubation, a bronchoscopy was performed to adjust the tube position to maintain an appropriate airway pressure and tidal volume. In the maintenance stage, the right internal jugular vein was cannulated, and BIS was performed to evaluate the depth of anesthesia. During the maintenance phase of anesthesia, patients in Group D received dexmedetomidine at a maintenance dose of 0.3 \( \mu \text{g} \times \text{kg} \times \text{h}^{-1} \) until 45 minutes after 1-lung ventilation. Patients in group N received the same amount of normal saline. At the beginning of the operation, 1-lung ventilation was immediately performed, and respiratory parameters were set to maintain the end-tidal pressure of carbon dioxide at 30 to 40 mm Hg. The respiratory parameters were adjusted according to blood gas measurements during the operation. The remifentanil dose and sevoflurane concentration were adjusted to maintain BIS between 40 and 60, and vecuronium was injected intermittently.

---

Figure 1. The inclusion flowchart of the patients.
2.5. Outcomes
The arterial partial pressure of oxygen (PaO₂), pulmonary shunt fraction (Qs/Qt), mean end-tidal sevoflurane concentration, mean arterial pressure (MAP), heart rate (HR) were compared between the 2 groups at 3-time points; after 5 minutes of 2-lung ventilation (T₀); after 30 minutes of OLV (T₁), and; after 45 minutes of OLV (T₂). Blood gas analysis was performed from the radial artery and internal jugular vein at T₀, T₁, and T₂. The arterial PaO₂, arterial oxygen saturation (SaO₂), hemoglobin (Hb), arterial partial pressure of carbon dioxide (PaCO₂), partial venous pressure of oxygen (PvO₂) and venous oxygen saturation (SvO₂) were recorded. The shunt fraction was computed using a standard formula: Qs/Qt = (C’CO₂–CaO₂)/ (C’CO₂–CvO₂) × 100%, while C’CO₂, CaO₂ and CvO₂ represented the oxygen content of pulmonary end-capillary, arterial and mixed venous blood, respectively. Meanwhile, the average MAP, HR and end-tidal concentration of sevoflurane (%) were recorded at T₀, T₁ and T₂. The dosage of sevoflurane from the beginning of OLV to 45 minutes of OLV was calculated (mL) as well according to the formula: Sevoflurane dosage (mL) = Sevoflurane concentration (%) × gas flow rate (L/minute) × time (minute) × (200.06/3666.24).

2.6. Statistical analysis
The data from the study results were organized and analyzed using SPSS 25.0 software (IBM SPSS, Inc., Chicago, IL). The continuous data were expressed as mean ± SD, except for gender, and body mass index between the 2 groups (P > .05). The lung function tests were similar in the 2 groups (P > .05) (Table 1). Continuous data were expressed as mean ± SD, and the qualitative data was expressed as rate and frequency. Continuous data were compared using the independent-samples t-test, and qualitative data were compared using the χ² test. A difference of more than 5% is considered significant (P < .05).

3. Results
3.1. Patient details
Fifty patients who were ready for surgery were initially included in this study. Two additional patients were excluded after the strict implementation of inclusion and exclusion criteria; 3 were also excluded because they refused to participate in the study. Subsequently, 1 patient was excluded from the trial group because of failed tracheal intubation and 2 patients with SpO₂ < 90%; 1 patient was excluded from the control group because of failed tracheal intubation and 1 with SpO₂ < 90%. Finally, a total of 40 patients were included in this study. There were 20 patients in the Dexmedetomidine infusion group and 20 in the control group with 0.9% saline infusion (Fig. 1). There were no statistical differences in age, gender, and body mass index between the 2 groups (P > .05). The lung function tests were similar in the 2 groups (P > .05) (Table 1).

3.2. Oxygenation details
Arterial PaO₂ decreased with the OLV time prolonging, and the levels were similar between Group D and Group N at T₀, T₁, and T₂, with no statistical significance (P > .05) (Table 2).

After 5 minutes of total lung ventilation (T₀), the intrapulmonary shunt fraction (Qs/Qt) level was similar between groups (P > .05). Qs/Qt was higher than T₀ at 30 minutes OLV (T₁) and 45 minutes OLV (T₂) in both groups. At T₁ and T₂, Qs/Qt was lower in Group D than in group N, with statistically significant differences (P < .05), as shown in Table 2.

3.3. Sevoflurane
The average sevoflurane end-tidal concentration (%) of the 2 groups was similar at T₀ (P > .05), while the concentration of group D was lower than that of group N at T₁, T₂ (P < .05). From the beginning of OLV to T₂, the dosage of sevoflurane in group D was less than that in group N (P < .05), as shown in Table 3.

3.4. Haemodynamics parameters
The MAP in Group D was lower than that in Group N at T₀, T₁ and T₂ (P < .05). At T₀, there was no statistically significant difference in HR between the groups (P > .05); at T₁ and T₂, the HR level in both groups was lower than that of T₀. The HR of Group D at T₁ and T₂ was lower than that of Group N (P < .05) (Table 4).

4. Discussion
We have not found clinical studies that reported the pulmonary effects of dexmedetomidine combined with sevoflurane in patients with 1-lung ventilation. This study aimed to investigate dexmedetomidine’s effect on intrapulmonary shunt in patients with sevoflurane maintained during 1-lung ventilation. The results revealed that dexmedetomidine could reduce the intrapulmonary shunt fraction and improve the HPV response during 1-lung ventilation. At the same time, it did not significantly promote the PaO₂ status during 1-lung ventilation. Previous studies have shown that dexmedetomidine combined
with isoflurane can improve HPV and the oxygenation of the body during OLV,\(^\text{[13]}\) which is consistent with our conclusion study.

Dexmedetomidine is an \(\alpha\) receptor agonist; studies have shown that vasoconstrictor drugs, such as adrenergic receptor agonists, can enhance HPV,\(^\text{[14,15]}\) and dexmedetomidine may enhance HPV by directly activating peripheral \(\alpha\) receptors and thereby causing pulmonary vessel constriction. Dexmedetomidine also acts on central \(\alpha\) receptors and inhibits sympathetic responses, which explains the lower MAP and HR at \(T_0\), \(T_1\) and \(T_2\) in Group D. However, there was no difference in HR between the groups at \(T_0\), which may be related to the significant stimulation of the double-lumen tube and the insufficient binding of dexmedetomidine to the central \(\alpha\) receptors. Dexmedetomidine has a synergistic effect on sedation. Studies also have proven that dexmedetomidine can reduce the dosage of inhaled and intravenous anesthetics during surgery.\(^\text{[16,17]}\) The results of this study confirmed that dexmedetomidine reduced sevoflurane dosage during 1-lung ventilation. Sevoflurane inhibits HPV dose-dependent; dexmedetomidine may reduce the dosage of sevoflurane through its synergistic effect, thus alleviating its inhibition of HPV. Xia et al.\(^\text{[18]}\) showed in a prospective clinical randomized controlled trial that dexmedetomidine enhances the effect of HPV by reducing the level of oxidative stress in the body during 1-lung ventilation, thereby improving the oxygenation status of patients. In addition, dexmedetomidine reduces the inflammatory response during 1-lung ventilation, thereby reducing lung injury; this effect may be associated with improved intrapulmonary shunting in patients.\(^\text{[19,20]}\)

Patient details and lung function tests were similar in the 2 groups. The baseline is comparable between the groups. After intubation, all patients underwent fiberbronchoscope positioning to adjust the double-lumen tube. We maintained an appropriate airway pressure and peripheral blood oxygen saturation during OLV. Thus, the effect on oxygenation caused by the imperfect alignment of the double-lumen tube is excluded. In addition, there were no statistical differences in \(\mathrm{PaO}_2\), \(Q/Q_t\), and average sevoflurane concentration between the 2 groups at \(T_0\). Therefore, dexmedetomidine is considered an essential factor affecting intrapulmonary shunt and HPV during 1-lung ventilation in the study. Because the excessive dose of dexmedetomidine can reduce blood pressure and heart rate, which is not conducive to the perfusion of organs and the safety of patients, in the trial, 0.75 \(\mu\)g/kg loading dose and 0.3 \(\mu\)g/(kg\(\cdot\)h) maintaining dose were used for pumping. During OLV, an intrapulmonary shunt is an important factor affecting oxygenation. HPV can help divert blood from the operative lung to the non-operative lung. The intrapulmonary shunt still occurs even in the presence of effective HPV.

This study used \(Q/Q_t\) and \(\mathrm{PaO}_2\) to evaluate body oxygenation. The results showed that \(Q/Q_t\) in Group D was lower than that in Group N during 1-lung ventilation. Still, there was no difference in \(\mathrm{PaO}_2\) between the groups, which shows that \(Q/Q_t\) is more effective in evaluating intrapulmonary shunt than \(\mathrm{PaO}_2\). Therefore, we can speculate that the choice of anesthetics is only one of the key factors affecting intrapulmonary shunt in clinical practice; studies have shown that temperature, \(\mathrm{pH}\), airway pressure, patient position and cardiac output all impact HPV.\(^\text{[21,22]}\)

This study still has certain limitations. Such as, due to surgical procedures and other reasons, blood gas analysis and data collection were only performed at \(T_0\), \(T_1\), and \(T_2\). In contrast, other time points during anesthesia were not evaluated. Patients were not tested for indicators related to oxidative stress and inflammatory responses during the procedures in this study, and the mechanism of action of dexmedetomidine has not been studied in depth. In addition, there was no comparison of airway pressure and cardiac output between groups. The small sample size study may affect the conclusion’s reliability, so multicenter, high-quality, large-sample clinical trials are needed to confirm the decision further.

### 5. Conclusion

In conclusion, compared with the control group, dexmedetomidine can reduce the intrapulmonary shunt fraction during 1-lung ventilation. Still, there is no statistical significance in the difference in arterial partial pressure of oxygen between groups. Haemodynamic stability and appropriate ventilatory maneuvers may be far more critical for achieving optimal oxygenation during OLV than the anesthetic agent’s choice.

### Acknowledgements

We thank Dr Liu jie and Dr Qilin Yang for revise the manuscript.

### Author contributions

Conceptualization: Yewen Wang.
Data curation: Yewen Wang.
Formal analysis: Chunzhi Gong.
Investigation: Chunzhi Gong.
Methodology: Chunzhi Gong.
Resources: Fei Yu.
Project administration: Quanyi Zhang.
Software: Fei Yu.

---

**Table 3**

| Lung ventilation | Average sevoflurane end-tidal concentration (%) | Dosage of sevoflurane (mL) |  
|------------------|-----------------------------------------------|-----------------------------|
| Group D          | Group N                                       |  
| \(70\)          | \(1.01 \pm 0.117 1.06 \pm 0.111\) \(215\) \(9.67 \pm 0.86 12.94 \pm 1.12\) \(<.001\) | \(\text{P value}\) Group D Group N \(\text{P value}\) |
| \(71\)          | \(1.29 \pm 0.078 1.47 \pm 0.083\) \(<.001\) | \(-\) | \(-\) | \(-\) |
| \(72\)          | \(1.30 \pm 0.076 1.48 \pm 0.083\) \(<.001\) | \(-\) | \(-\) | \(-\) |

**Table 4**

| Lung ventilation | MAP (mm Hg) | HR (bpm) |
|------------------|-------------|----------|
| Group D          | Group N     | \(\text{P value}\) Group D Group N \(\text{P value}\) |
| \(70\)          | \(82.80 \pm 6.246\) | \(88.65 \pm 6.518\) | \(\text{.018}\) | \(76.50 \pm 8.636\) | \(81.10 \pm 9.026\) | \(\text{.108}\) |
| \(71\)          | \(75.20 \pm 4.526\) | \(84.60 \pm 6.809\) | \(<.001\) | \(63.0 \pm 6.340\) | \(72.80 \pm 6.685\) | \(<.001\) |
| \(72\)          | \(75.85 \pm 4.771\) | \(85.55 \pm 6.525\) | \(<.001\) | \(63.75 \pm 5.893\) | \(73.50 \pm 6.245\) | \(<.001\) |

Values are presented as mean ± standard deviations. bpm = beats per minute, HR = heart rate, MAP = mean arterial pressure.
References

[1] Ng A, Swanevelder J. Hypoxaemia during one-lung anaesthesia. Continuing Educ Anaesthesia Crit Care Pain. 2010;10:117–22.

[2] Biricik E, Karacaer F, Gunes Y, et al. Effect of one-lung ventilation on blood sevoflurane and desflurane concentrations. J Cardiothorac Vasc Anesth. 2019;33:442–9.

[3] Marraro GA. Selective bronchial intubation for one-lung ventilation and independent-lung ventilation in pediatric age: state of the art. Zhongguo Dang dai er ke za zhi= Chin J Contemporary Pediatrics. 2020;22:543–54.

[4] Schwarzkopf K, Klein U, Schreiber T, et al. Oxygenation during one-lung ventilation: the effects of inspired fraction of oxygen. Anesthesia Analgesia. 2001;92:842–7.

[5] Chigurupati K, Raman SP, Pappu UK, et al. Effect of one-lung ventilation on arterial oxygenation pressure, mean arterial pressure and heart rate variations following one-lung ventilation in thoracic surgeries. Iranian Red Crescent Med J. 2014;16:e15809.

[6] Ehrenfeld JM, Funk LM, Van Schalkwyk J, et al. The incidence of hypoxemia during surgery: evidence from two institutions. Can J Anesthesia/Journal canadien d’anesthésie. 2010;57:888–97.

[7] Attar AS, Tabari M, Rahnamazadeh M, et al. A comparison of effects of propofol and isoflurane on arterial oxygenation pressure, mean arterial pressure and heart rate variations following one-lung ventilation in thoracic surgeries. Iranian Red Crescent Med J. 2014;16:e15809.

[8] Cho YJ, Kim TK, Hong DM, et al. Effect of desflurane-remifentanil vs propofol-remifentanil anaesthesia on arterial oxygenation pressure, mean arterial pressure and heart rate variations following one-lung ventilation in thoracic surgery. Minerva Anestesiol. 2011;77:534–6.

[9] Della Rocca G, Coccia C. Ventilatory management of one-lung ventilation. Minerva Anestesiol. 2011;77:534–6.

[10] Lumb AB, Slinger P. Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications. Anesthesiology. 2015;122:932–46.

[11] Xu B, Gao H, Li D, et al. Nebulized dexmedetomidine improves pulmonary shunt and lung mechanics during one-lung ventilation: a randomized clinical controlled trial. PeerJ. 2020;8:e9247.

[12] Talke P, Richardson CA, Senn M, et al. Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. Anesthesia Analgesia. 1997;85:1136–42.

[13] Xia R, Yin H, Xia Z-y, et al. Effect of intravenous infusion of dexmedetomidine combined with inhalation of isoflurane on arterial oxygenation and intrapulmonary shunt during single-lung ventilation. Cell Biochem Biophys. 2013;67:1547–50.

[14] Moutaifs M, Dalibon N, Colchen A, et al. Improving oxygenation during bronchopulmonary lavage using nitric oxide inhalation and almitrine infusion. Anesthesia Analgesia. 1999;89:302–4.

[15] Silva-Costa-Gomes T, Gallart L, Valles J, et al. Low-vs high-dose almitrine combined with nitric oxide to prevent hypoxia during open-chest one-lung ventilation. Br J Anaesth. 2005;95:410–6.

[16] Mariappan R, Ashokkumar H, Kuppuswamy B. Comparing the effects of oral clonidine premedication with intraoperative dexmedetomidine infusion on anesthetic requirement and recovery from anesthesia in patients undergoing major spine surgery. J Neurosurg Anesthesiol. 2014;26:192–7.

[17] Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med. 2010;36:926–39.

[18] Xia R, Xu J, Yin H, et al. Intravenous infusion of dexmedetomidine combined isoflurane inhalation reduces oxidative stress and potentiates hypoxia pulmonary vasoconstriction during one-lung ventilation in patients. Mediators Inflamm. 2013;2015:238041.

[19] Wu C-Y, Lu Y-F, Wang M-L, et al. Effects of dexmedetomidine infusion on inflammatory responses and injury of lung tidal volume changes during one-lung ventilation in thoracoscopic surgery: a randomized controlled trial. Mediators Inflamm. 2018:2018;2575910.

[20] Bai YX, Zhang JH, Zhao BC, et al. Dexmedetomidine attenuates one-lung ventilation associated lung injury by suppressing inflammatory responses: a systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2021;48:1203–14.

[21] Dunham-Snary KJ, Wu D, Sykes EA, et al. Hypoxic pulmonary vasoconstriction: from molecular mechanisms to medicine. Chest. 2017;151:181–92.

[22] Swenson ER. Hypoxic pulmonary vasoconstriction. High Altitude Med Biol. 2013;14:101–10.